Zinc PyrithioneCAS# 13463-41-7 |
- Lansoprazole
Catalog No.:BCC1058
CAS No.:103577-45-3
- Esomeprazole Sodium
Catalog No.:BCC4376
CAS No.:161796-78-7
- Esomeprazole Magnesium
Catalog No.:BCC5007
CAS No.:161973-10-0
- Esomeprazole Magnesium trihydrate
Catalog No.:BCC1559
CAS No.:217087-09-7
- Lansoprazole sodium
Catalog No.:BCC4298
CAS No.:226904-00-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 13463-41-7 | SDF | Download SDF |
| PubChem ID | 26041 | Appearance | Powder |
| Formula | C10H8N2O2S2Zn | M.Wt | 317.7 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 33.33 mg/mL (104.91 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | zinc;1-oxidopyridin-1-ium-2-thiolate | ||
| SMILES | [Zn++](|[S-]c1cccc[n+]1[O-])|[S-]c2cccc[n+]2[O-] | ||
| Standard InChIKey | OTPSWLRZXRHDNX-UHFFFAOYSA-L | ||
| Standard InChI | InChI=1S/2C5H5NOS.Zn/c2*7-6-4-2-1-3-5(6)8;/h2*1-4,8H;/q;;+2/p-2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Zinc Pyrithione is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump.
Target: Proton Pump
Zinc pyrithione is considered as a coordination complex of zinc. The pyrithione ligands, which are formally monoanions, are chelated to Zn 2+ via oxygen and sulfur centers. In the crystalline state, zinc pyrithione exists as a centrosymmetric dimer, where each zinc is bonded to two sulfur and three oxygen centers. In solution, however, the dimers dissociate via scission of one Zn-O bond. Zinc pyrithione, which is a dimer but is probably biologically active as a monomer, induces plasma membrane depolarization with half-maximal effect (K1/2) of about 0.3 mM [1]. Zinc pyrithione is an unusual synthetic potentiator that potently activates both heterologous and native M channels by inducing channel opening at the resting potential [2]. Zinc pyrithione rapidly accumulated in the tissues of the exposed mussels, proportionately to both exposure concentration and time. Even though the 7-d median lethal concentration (LC50) = 8.27 μM established here appears high with respect to reported ZnPT environmental concentrations, the results indicate that this biocide could represent a threat for marine organisms in coastal environments and that further investigations on its biological effects at sublethal doses are needed [3]. References: | |||||
Zinc Pyrithione Dilution Calculator
Zinc Pyrithione Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.1476 mL | 15.7381 mL | 31.4762 mL | 62.9525 mL | 78.6906 mL |
| 5 mM | 0.6295 mL | 3.1476 mL | 6.2952 mL | 12.5905 mL | 15.7381 mL |
| 10 mM | 0.3148 mL | 1.5738 mL | 3.1476 mL | 6.2952 mL | 7.8691 mL |
| 50 mM | 0.063 mL | 0.3148 mL | 0.6295 mL | 1.259 mL | 1.5738 mL |
| 100 mM | 0.0315 mL | 0.1574 mL | 0.3148 mL | 0.6295 mL | 0.7869 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Zinc pyrithione is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump.
- Eriocitrin
Catalog No.:BCN1208
CAS No.:13463-28-0
- Stavudine sodium
Catalog No.:BCC4263
CAS No.:134624-73-0
- ML 218 hydrochloride
Catalog No.:BCC6207
CAS No.:1346233-68-8
- SA 57
Catalog No.:BCC6280
CAS No.:1346169-63-8
- Planchol E
Catalog No.:BCN6882
CAS No.:1346137-02-7
- LY2795050
Catalog No.:BCC1719
CAS No.:1346133-08-1
- ML 154
Catalog No.:BCC8022
CAS No.:1345964-89-7
- 5,7-Di-O-methylquercetin
Catalog No.:BCN3386
CAS No.:13459-07-9
- CYM 50308
Catalog No.:BCC6260
CAS No.:1345858-76-5
- Altiratinib
Catalog No.:BCC6385
CAS No.:1345847-93-9
- Arginase inhibitor 1
Catalog No.:BCC4034
CAS No.:1345808-25-4
- ETP-46464
Catalog No.:BCC3913
CAS No.:1345675-02-6
- ML 240
Catalog No.:BCC5604
CAS No.:1346527-98-7
- GSK503
Catalog No.:BCC6386
CAS No.:1346572-63-1
- GSK126
Catalog No.:BCC1604
CAS No.:1346574-57-9
- GSK621
Catalog No.:BCC6517
CAS No.:1346607-05-3
- GSK343
Catalog No.:BCC1607
CAS No.:1346704-33-3
- Lamivudine
Catalog No.:BCC3801
CAS No.:134678-17-4
- Linderane
Catalog No.:BCN5023
CAS No.:13476-25-0
- A 412997 dihydrochloride
Catalog No.:BCC6224
CAS No.:1347744-96-0
- 6''-O-Acetylglycitin
Catalog No.:BCN3866
CAS No.:134859-96-4
- 8-M-PDOT
Catalog No.:BCC6901
CAS No.:134865-70-6
- 4-P-PDOT
Catalog No.:BCC6900
CAS No.:134865-74-0
- SAR245409
Catalog No.:BCC2534
CAS No.:934493-76-2
Estrogenic activity of zinc pyrithione: an in vivo and in vitro study.[Pubmed:28183164]
Environ Health Toxicol. 2017 Feb 9;32:e2017004.
Zinc Pyrithione (ZP) is commonly used to prevent dandruff and seborrheic dermatitis. Many consumers are exposed daily to high doses of ZP, causing serious concerns about its toxicity. The reproductive and developmental toxicities were previously reported in pregnant rats. However, the estrogenic activity of ZP at varying degrees of exposure has been rarely studied. Thus, we performed an uterotrophic assay, E-screen assay, and gene expression profiling to assess the estrogenic activity of ZP. For the uterotrophic assay, ZP (2, 10, or 50 mg/kg/d) was subcutaneously administered to ovariectomized rats every day for three days. Uteri were extracted 24 hours after the last dose. Then, wet and blotted uterine weights were measured. For the E-screen essay, MCF-7 cells (a breast cancer cell line) were exposed to 10(-9) to 10(-6) M of ZP, and cell proliferation was then measured. For the gene expression analysis, changes of gene expression levels in uterine samples taken for the uterotrophic assay were analyzed. In the uterotrophic assay, the concentration of ZP had no significant effect on uterine weight. In the E-screen assay, ZP at any concentration showed no significant increase in MCF-7 cell proliferation, compared to the control group. However, 10(-6) M of ZP significantly reduced cell viability. The changes in gene expression slightly differed between the ZP and control groups. The in vivo and in vitro assays, together with gene expression analysis, demonstrated that ZP showed no significant estrogenic activity.
Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases.[Pubmed:28086217]
Oncotarget. 2017 Feb 21;8(8):13942-13956.
The ubiquitin-proteasome system (UPS) plays a central role in various cellular processes through selectively degrading proteins involved in critical cellular functions. Targeting UPS has been validated as a novel strategy for treating human cancer, as inhibitors of the 20S proteasome catalytic activity are currently in clinical use for treatment of multiple myeloma and other cancers, and the deubiquitinase activity associated with the proteasome is also a valid target for anticancer agents. Recent studies suggested that Zinc Pyrithione, an FDA-approved antidandruff agent, may have antitumor activity, but the detailed molecular mechanisms remain unclear. Here we report that Zinc Pyrithione (ZnPT) targets the proteasome-associated DUBs (USP14 and UCHL5) and inhibits their activities, resulting in a rapid accumulation of protein-ubiquitin conjugates, but without inhibiting the proteolytic activities of 20S proteasomes. Furthermore, ZnPT exhibits cytotoxic effects against various cancer cell lines in vitro, selectively kills bone marrow cells from leukemia patients ex vivo, and efficiently inhibits the growth of lung adenocarcinoma cancer cell xenografts in nude mice. This study has identified Zinc Pyrithione, an FDA-approved pharmacological agent with potential antitumor properties as a proteasomal DUB inhibitor.
Loss of ErbB2-PI3K/Akt signaling prevents zinc pyrithione-induced cardioprotection during ischemia/reperfusion.[Pubmed:28119233]
Biomed Pharmacother. 2017 Apr;88:309-324.
OBJECTIVES: The purpose of this study was to determine if zinc homeostasis is affected during ischemia/reperfusion, if so, whether Zinc Pyrithione limits myocardial cell death and improves hemodynamics when administered as an adjunct to reperfusion and if ErbB receptor tyrosine kinases that are important for the long-term structural integrity of the heart are indispensable for reperfusion salvage. METHODS: Isolated perfused rat hearts were subjected to 35min of global ischemia and reperfused for 120min to determine the relative intracellular zinc levels by TSQ staining. The hearts were reperfused in the presence of incremental concentrations of Zinc Pyrithione for the first 10min during reperfusion. Silencing or blockade of ErbB2 using a monoclonal antibody, ErbB2 kinase inhibition and PI3kinase inhibition was used to study their critical role in Zinc Pyrithione-induced cardioprotection. RESULTS: We found that there was a profound decrease in intracellular zinc after ischemia/reperfusion resulting in increased apoptosis, caspase-3 activation, and infarct size. A dose-dependent reduction of infarct size with Zinc Pyrithione in the range of 5-20mumol/l (optimal protection was seen at 10mumol/l with infarct size of 16+/-2% vs. I/R vehicle, 33+/-2%, p<0.01). Increased TUNEL staining and caspase-3 activity observed after ischemia/reperfusion were attenuated by Zinc Pyrithione administration during the reperfusion. Moreover, this protection was sensitive to silencing and blockade of ErbB2, inhibition of ErbB2 kinase activity or PI3-kinase activity. Western blot analysis revealed that Zinc Pyrithione resulted in decreased caspase-3 activation, rapid stabilization of ErbB2/ErbB1 heterodimers, and increased activation of PI3K/Akt signaling cascade. CONCLUSIONS: Zinc Pyrithione attenuates lethal perfusion-induced injury in a manner that is reliant on ErbB2/PI3K/Akt activity.
A physiologically based pharmacokinetic model for the broad-spectrum antimicrobial zinc pyrithione: I. Development and verification.[Pubmed:28085645]
J Toxicol Environ Health A. 2017;80(2):69-90.
The broad-spectrum antimicrobial Zinc Pyrithione (ZnPT) is used in numerous products ranging from in-can preservative/mildicide in paints to antidandruff shampoo. Although products containing ZnPT have a long history of safe use, regulatory agencies routinely set limits of exposure based upon toxicological considerations. The objective of this study was to create a physiologically based pharmacokinetic (PBPK) model for ZnPT in the rat for improving dose-response analysis of ZnPT-induced toxicity, reversible hindlimb weakness, the endpoint that has been used as the basis for ZnPT risk assessments. A rat oral PBPK model was developed that includes compartments for plasma, liver, kidneys, muscle, brain, and rapidly and slowly perfused tissues. Pyrithione metabolism to 2-(methylsulfonyl)pyridine (MSP) and glucuronide conjugates was incorporated into the model. The model was parameterized and optimized based upon data from single-dose intravenous (iv) and oral gavage pharmacokinetic studies of radiolabeled pyrithione ([(14)C]PT) administered as zinc [(14)C]-pyrithione (Zn-[(14)C]PT) to adult female rats. It was further evaluated and refined using data from repeated, multidose oral gavage and dietary studies of Zn[(14)C]PT in the adult female rat that included measurements of plasma PT concentration, the putative toxic species. The model replicated the observed short-term elimination kinetics of PT in plasma and [(14)C]PT in whole blood following single doses and longer term temporal patterns of plasma and blood concentrations during repeated dosing schedules. The model also accounted for production and rapid elimination of S-glucuronide conjugates (SG) of 2-pyridinethiol and 2-pyridinethiol-1-oxide in urine, as well as production and slower elimination of MSP, the major [(14)C]PT species in blood within several hours following administration of ZnPT. The model provided internal dosimetry predictions for a benchmark dose (BMD) analysis of hindlimb weakness in rats, and was used to combine gavage and dietary studies into a single internal dose-response model with area under the curve (AUC) for plasma PT as the internal dose metric. This PBPK model has predictive validity for calculating internal doses of PT and/or [(14)C]PT from different routes of exposure in the rat.
